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Introduction
Because the European pharmaceutical 
industry is lagging seriously behind its 
competitors, mainly in the US, and seems 
to be particularly slow in harnessing the 
benefits of the revolution in biotechnology, 
the European Commission requested the 
Research Directors’ Group of the European 
Federation of Pharmaceutical Industries’ 
Associations (EFPIA) to identify the main 
barriers to innovation in Life Sciences 
research in Europe with the objective of 
establishing a new initiative for Innovative 
Medicines. This is because one of the major 
objectives of the European Union is to 
build the most competitive and dynamic 
knowledge-based economy in the world 
by 2010, a key element of which is to 
strengthen the science base in Europe. 
In this context, the biopharmaceutical 
environment is characterised particularly 
by its focus on science and innovation. 
It is therefore essential to revitalise this 
environment so as to make it become 
more competitive, not by fast-tracking the 
production of new compounds, but more 
by a root and branch review of the entire 
pharmaceutical R&D process.  This “bench 
to bedside” approach would entail the 
development of a new “toolbox”, developed 
through collaboration between all 
stakeholders (patients, industry, including 
the SME sector, regulators, clinical and 
academic researchers, etc.), that would 
constitute the means to streamline the R&D 
process and thereby ensure that patients 
obtain new medicines faster without 
compromising safety. 
The development of a new drug is 
a long, resource intensive and complex 
process. The overall cost for just one 
compound is estimated to be e868,000,000 
at prices for the year 2000.1 The possibility 
of failure to reach the market by the end 
is high and the project may fail for many 
reasons at many points in its evolution. 
Data on product attrition rates indicate that 
the probability of a drug candidate passing 
from pre-clinical stages (first GLP toxicity 
study) to market is 6% or less.2 Improving 
these odds depends upon a concerted 
research effort to overcome the perceived 
bottlenecks in this R&D development 
pathway so as to bring more efficacious 
and safer drugs to the market more quickly, 
resulting in a direct benefit for patients.
The greatest need for the 
pharmaceutical industry is to detect the 
possibility of failure at the earliest stage 
as possible, and it is in this context that 
advances in basic biomedical science within 
the European research community could 
make the greatest contribution. 
At the same time, the European 
Commission also developed the Joint 
Technology Initiative concept as a means of 
identifying and resolving major economic, 
technological or societal challenges that 
have Research and Development aspects. 
These will generate effective public-private 
partnerships between all relevant 
stakeholders, whether they are companies, 
research institutions, the financial world 
and regulatory authorities at the European 
level to define a common research agenda 
which should mobilise a critical mass of 
- national and European - public and private 
resources. Joint Technology Initiatives are 
expected to contribute to achieving the 
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The Joint Technology Initiative for Innovative Medicines for 
European Citizens is proposed within the context of the European 
Commission’s proposals for the Seventh Framework Programme 
(2007-2013) and proposes clear practical paths to accelerate the 
development of safe and more effective approved new medicines. 
This will be achieved by stimulating integrated forms of co-operation 
in research and development, in particular through a public-private 
partnership (PPP), to be established especially for this purpose. This 
will become operational in 2007 and current calculations forecast 
investments of approximately €440 million per year.
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objective for Europe of becoming “…the 
most competitive and dynamic knowledge-
based economy in the world capable of 
sustainable economic growth with more and 
better jobs and greater social cohesion”. 
This is referred to as the Lisbon objective, 
which amongst others, aims to improve 
the research climate in Europe in terms 
of better growth and competitiveness and 
increasing investment in R&D towards the 
% of overall European GDP. This intention 
was published in the Communication from 
the Commission entitled “Science and 
technology, the key to Europe’s future 
– Guidelines for future European Union 
policy to support research”.  
Clearly, a Joint Technology Initiative for 
Innovative Medicines was the answer.
With this in mind, industry responded 
by identifying  areas for action in 
agreement with key stakeholders:
• Better prediction of safety
• Better prediction of efficacy
• Knowledge management
• Education and training
Through a series of several workshops 
involving over 00 experts in research and 
development representing all stakeholder 
groups (academia, large pharmaceutical 
industries, the SME sector, regulatory 
agencies including the European Medicines’ 
Agency, patient organisations and financial 
institutions) were consulted and came to 
the following conclusions on each of the 
above issues. 
Better prediction of safety
Pre-clinical safety, or toxicological 
issues are responsible for 20% of the overall 
attrition rate for candidate medicinal 
products in pharmaceutical development. 
There is greater public and media scrutiny 
of pharmaceuticals and regulatory decision-
making than before and a perceived 
overall weakness of the post-marketing 
surveillance system. Regulatory authorities 
have accordingly become more risk-averse, 
requiring ever broader and more restrictive 
risk management strategies to avoid such 
problems, with the need for expanded 
studies to quantify potential serious 
adverse events, even those of great rarity 
or scientific improbability. There is an 
increasing tendency for the approval of 
more restricted indications (with requests 
for increased data for broader indications) 
slowing down approval for marketing 
and delayed patient access to innovative 
medicines that address medical needs. 
The following suggestions from the 
consulted experts are intended to enhance 
this overall process:
• Create a European Centre of Drug Safety 
to identify and co-ordinate research 
needs in safety sciences, including the 
development of a pan-European Safety 
Sciences Programme
• Establish a framework for biomarker 
development which will evaluate human 
relevance and regulatory utility 
• Develop in silico methods for better 
prediction of safety
• Study the relevance of rodent non-
genotoxic carcinogens
• Tackle intractable toxicity
• Improve healthcare provider training in 
detection of adverse drug reactions
• Development of databases including 
knowledge management tools of data 
analysis in pharmacovigilance
• Improve communication between 
patients, physicians and other healthcare 
providers in pharmacovigilance 
Greater use will need to be made 
of in-silico tools and newly emerging 
disciplines such as toxicogenomics*, 
toxicoproteomics and metabonomics in 
*  The collection, interpretation, and storage of information about gene and protein activity in order to identify toxic substances in the environment and to help treat 
people at the greatest risk of diseases caused by environmental pollutants or toxicants
  The use of global protein expression technologies to understand better environmental and genetic factors, both in episodes of acute exposure to toxicants and in the 
long-term development of disease
  Used interchangeably with “metabolomics”, signifying the quantitative measurement of the dynamic multiparametric metabolic response of living systems to 
pathophysiological stimuli or genetic modification
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an integrated fashion so as to get a better 
idea and sooner of a candidate compound’s 
chances of making it to market.  
Better prediction of efficacy
A number of issues emerge as suitable 
and necessary for action: 
Biomarkers
A biomarker is defined as “a 
characteristic that is objectively measured 
and evaluated as an indicator of normal 
biologic processes, pathogenic processes, or 
pharmacologic responses to a therapeutic 
intervention”.  They can be used as tools 
to understand the biology of a disease 
but also to understand the effects of a 
new drug sooner than at present. This 
can result in better and earlier decision-
making about whether to proceed with 
the development of a compound, reducing 
late-stage and more costly attrition. This 
could mean benefits such as : increasing 
the probability of program success and 
reduced cycle times, matching patients with 
therapy; faster optimisation of therapy; 
improved compliance with therapy, reduced 
complications of therapy and disease, more 
efficient drug development, more efficient 
healthcare delivery and ultimately reduced 
societal healthcare burden.
Patient involvement
This is perhaps the most important part 
of the medicine development process and 
consumes over 50% of the time available. 
One of the major components is the 
patient recruitment phase which can last 
on average twelve months if not longer. 
Reducing its duration will have a substantial 
effect on the time needed to develop new 
medicines provide a competitive edge 
in terms of performing clinical trials. A 
potential means of achieving this could be 
through education of patients about the 
benefits of participating in research. They 
should not only be informed about the 
outcome of the clinical research but also be 
involved in the design of the study. This is 
important for developing a more patient-
oriented approach to treatment and for 
their participation in an educational process 
involving not just them, but also carers 
and researchers to ensure best treatment 
outcomes. Issues to be resolved include 
the precarious nature of their funding, the 
establishment and maintenance of patient 
records and databases of information and 
quality of life measurements as outcomes to 
clinical trials that identify most closely with 
their experiences. 
Regulatory approvals
As final judge of the risk/benefit 
ratio for each new application, regulatory 
authorities are most sensitive to public 
concerns about medicines as reflected 
in expanded requirements to outrule the 
possibility of serious and other adverse 
events. This can result in serious delays in 
obtaining marketing authorisations for new 
medicines to redress medical needs and 
the following items have been identified as 
suitable for action: 
• Improved dialogue with regulators during 
drug development prior to regulatory 
approval so as to reduce requests for 
additional data following submission,
• Increased acceptance by regulatory 
authorities of biomarkers and surrogate 
clinical end points to clinical trials,
• Increase the involvement of other 
stakeholders, especially patients, in the 
regulatory review process,
• Develop methodologies for data 
collection on the risks and benefits of 
medicines once they are available in a 
real world setting,
• Ensure appropriate use of the conditional 
approval process for innovative new 
medicines with an adequate safety 
profile,
• Develop with regulators proposals to 
increase sharing of data, for example on 
the placebo arms of clinical trials,
• Encourage discussion on a more flexible 
approach to clinical trials that reflects 
the individual needs of particular disease 
areas, e.g. quality of life issues that 
identify closely with patient needs
Other recommendations are as follows : 
• Develop better understanding of disease 
mechanisms,
• Develop in vitro and in vivo models 
predictive of clinical efficacy,
• Develop in silico simulations of disease 
pathology,
• Create disease-specific European Imaging 
Networks,
• Create disease-specific European Centres 
for validation of omics-based biomarkers,
• Co-ordinate the development of national 
patient networks,
• Form European consortia to address value 
demonstration,
• Develop a framework in partnership with 
the regulators for innovative clinical trial 
design and analysis.
Knowledge management
The vast sources of scientific and 
technical knowledge that need to be 
linked together under the auspices of the 
Joint Technology Initiative for Innovative 
Medicines are extremely diverse with regard 
to origin, availability, ownership, scientific 
content and many other features. This 
diversity, the complexity of underlying 
science and the means of drawing 
meaningful conclusions from them are also 
likely to increase with time.
It must therefore be asked what 
information is needed (and what is not 
needed) from such information sources, 
what tools are need to extract such 
information, how can it be analysed in 
such a way that will enable meaningful 
conclusions to be drawn from it so as to 
enable accurate predictions to be made 
that are relevant to real-life situations. The 
following issues need to be borne in mind. 
Firstly and from the users’ point of 
view, the knowledge management system 
must reflect the way those who utilise it 
(here : the biopharmaceutical community 
stakeholders as mentioned above) work 
together and it must integrate smoothly 
in their day-to-day environment. In 
particular, it must provide relevant, simple 
and intuitive access to various information 
sources and yet be capable of organising 
it according to content, allow for data 
to be integrated or pooled, analysed and 
constructed into models that reflect real-life 
situations. Examples include tasks as simple 
as identifying a clinical expert with a 
particular profile or as complex as pooling 
together the placebo arms of several clinical 
trials into one large pool that can serve as 
one virtual half of a clinical study versus a 
comparator product. It should also allow for 
issues such as virtual meetings, knowledge 
sharing, forums, discussions, etc., open to 
whole community, as well as within context-
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defined sub-communities.
From the technical point of view, 
the key objective is to ensure seamless 
data integration across a broad range of 
heterogeneous scientific, computer and 
other technical resources across differing 
organisations and networks. Further, 
it should be adaptable enough to be 
based upon existing and emerging data 
representation standards and yet be able to 
satisfy unpredictable requirements as they 
emerge. 
From this seemingly impossible 
set of requirements, only the broadest 
recommendations can be made and these 
appear to be as follows:
• To develop enhanced knowledge 
representation models and data exchange 
standards for complex systems,
• To build a core reference database of 
validated experimental data extracted 
from the literature,
• To design standards for and build an 
expert tool to allow the federation of 
local databases in a secured environment.
In principle, the required flexibility 
of the future platform can be met by 
designing a federated environment based 
on existing stand-alone tools, components 
and resources, based on open common 
architectural standards that can be adapted 
to contemporary needs and capable of 
dynamic reconfiguration.
Education and training
The goal of education and training 
activities associated with the Joint 
Technology Initiative for the Innovative 
Medicines Initiative should be to support 
the interdisciplinary education process 
essential to the bioscience sector. This 
entails the development of a new concept 
referred to as “Translational Medicne” 
or Translational Science”, which may be 
defined as: 
“…a comprehensive European-
based approach aimed at a common 
understanding throughout all relevant 
scientific disciplines of the research and 
development steps that bring a new 
biochemical substance or technique (NCE, 
biotechnological intervention, etc.) to 
market as a therapeutic clinically safe 
and effective intervention.” 
This will require the establishment 
of a pan-European platform responsible 
for the education and training of current 
and future professionals involved in 
the biopharmaceutical research and 
development process, including lifecycle 
management. It will need to be based upon 
existing centres of excellence within the 
disciplines and therefore not be a new or 
parallel entity. 
Its main priorities will be as follows: 
• To act as a central coordinating unit 
and an advisory education and training 
council
• To develop programmes for integrated 
medicine development, ethics committees 
and patient organisations, 
• To develop programmes for safety 
scientists within pharmaceutical R&D
• To develop Regulatory Affairs-based 
programmes
• To develop appropriate training 
programmes for biostatisticians, 
bioinformaticians and biomedical 
informaticians
• To develop programmes for 
pharmaceutical medicine professionals
Patients and their representatives 
should be involved as far as possible 
since they can make a key contribution to 
the determination of what and how the 
professionals acquire skills and knowledge 
of greatest use to the public. Furthermore, 
there is a need for ongoing training for 
experts, or what is referred to as Continuous 
Professional Development, to keep up to 
date with developments in science and 
technology. This will entail the training of 
specialists to acquire knowledge from areas 
other than those they graduated from, e.g. 
business and finance training for clinical 
scientists working, for example in the SME 
sector.
Following a consultation process with 
relevant stakeholders, a number of gaps 
will need to be filled in the Education 
and Training process that fall under the 
following headings: 
• Increased scientific interaction, in terms 
of information and personnel, between 
the academic world and industry and 
regulatory authorities on the other, 
to facilitate the sharing and exchange 
of knowledge. In most European 
countries this is characterised mainly 
by a brain-drain to industry, mostly for 
financial reasons. 
• Safety scientists with a much broader 
spectrum of knowledge drawn from 
areas such as primary and secondary 
pharmacology, functional genomics, 
safety pharmacology, physiology, 
pathophysiology, physical chemistry, 
animal and clinical toxicology, cellular 
biology, biochemistry and animal 
physiology, 
• Clinical pharmacologists, non-clinical and 
clinical,
• Physicians specialised in pharmaceutical 
medicine,
• Specialists in bioinformatics, 
biostatistics, systems pharmacology and 
physiology (in vivo whole organism), 
medical imaging  and in-silico modelling, 
• Regulatory personnel trained in 
disciplines arising from the Clinical Trials 
(GCP) Directive,5 namely inspectors, 
clinical investigators, monitors, clinical 
research associates and members of 
ethics committee.  
• A better understanding of the process 
of medicines development to be 
communicated to journalists, venture 
capitalists and the general public. 
The success of these measures will 
depend on the support from all relevant 
stakeholders, especially the European 
biomedical industry, academia, scientific 
and professional societies, patient groups, 
regulatory bodies and the European 
Commission. Minimal bureaucracy will be 
the key to ensuring maximum flexibility and 
rapid action.
Legislative developments
The first and most important of these 
is Regulation (EC) 726/200,6 which 
governs the European Regulator, the 
European Medicines’ Agency (EMEA) as well 
as the scope of the centralised marketing 
authorisation procedure.Up to recently, this 
has been a requirement for products derived 
from biotechnology and optional for new 
chemical entities. Centralised assessment 
is now compulsory for products intended 
for use in the treatment of AIDS, cancer, 
neurodegenerative disorders and diabetes 
mellitus. From May 20, 2008, this will be 
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extended to cover products used to treat 
autoimmune diseases and other immune 
dysfunctions, as well as viral diseases. As a 
consequence, many more new products will 
be assessed via this method.
Three new marketing authorisations 
have also been introduced: accelerated 
authorisation, compassionate use and 
“exceptional circumstances”. The accelerated 
procedure (6, art. 1)9 comprises a 150-day 
review as opposed to the usual 210 days 
and covers products, which represent a 
major public health or other therapeutic 
interest. This was first developed by the 
EMEA in 2001 so as to expedite the review 
of marketing authorisation applications for 
life-threatening or incapacitating disorders. 
In order to be evaluated under this process, 
a product must be indicated for a serious 
disease, it must be the only possible 
treatment and it must possess exceptionally 
high therapeutic benefit.
“Exceptional circumstances” (6 art. 1)8 
refers to approval for marketing of products 
where comprehensive information cannot be 
provided by the applicant (small study size 
due to the overall rarity of the condition 
e.g. in certain orphan indications), or where 
collecting such data would be contrary to 
accepted medical ethics. Such products 
would be available by prescription only, 
be subject to strict medical supervision 
and their package leaflets would have to 
be formulated in such a way as to draw 
attention to the fact that many particulars 
concerning the product are as yet 
unavailable or inadequate. 
“Compassionate use” (6, art. 8),7 refers 
to a specific provision that remains to be 
introduced, which will be complementary 
to national legislation and will provide 
an option to Member States who wish 
to receive a CHMP opinion regarding the 
conditions for compassionate use of a 
specific medicinal product which falls within 
the scope of the regulation. 
Each of the following specific criteria 
should be fulfilled: 
• The medicinal product is to be made 
available to patients with a chronically 
or seriously debilitating disease, or a life 
threatening disease, and who cannot be 
treated satisfactorily by an authorised 
medicinal product in Europe, 
• The compassionate use programme is 
intended for a group of patients, 
• The medicinal product is either the 
subject of an application for a centralised 
marketing authorisation or is undergoing 
clinical trials in the European Union 
and/or elsewhere. 
A Conditional Marketing Authorisation,8 
separate from other foregoing legal 
provisions, is also planned which allows 
for a product to be granted temporary 
approval under Regulation 726/2006 for 
one year only and subject to annual review 
by EMEA.  In particular, full clinical data 
will have to be provided post-approval, but 
the applicant will still have to provide full 
preclinical (animal) information at the time 
of application as well as demonstrate a 
positive benefit/risk ratio of the drug. This 
is intended for orphan medicinal products 
and products intended for rapidly arising 
public health threats. 
Pharmacovigilance and post-marketing 
surveillance receive greater attention. 
This places even greater emphasis on the 
continuous monitoring of the risk/benefit 
ratio of marketed products on an ongoing 
basis, taking account of all post-approval 
safety information. Marketing Authorisation 
Holders will be required to have 
“permanently and continuously at [their] 
disposal” a person appropriately qualified 
in pharmacovigilance. This person is 
responsible for managing pharmacovigilance 
systems and in particular, the submission 
of pharmacovigilance or Periodic Safety 
Update Reports (PSURs) to the competent 
authorities, which will follow a tighter 
timetable than before. These will have to 
be submitted every 6 months after approval 
until the product is marketed. After this has 
started, PSURs must be submitted every 6 
months for the first two years, then once 
a year for another 2 years and at -yearly 
intervals thereafter. Regulatory authorities 
will be allowed to request a PSUR at any 
time at their discretion.
Directive 200/27/EC,9 which amends 
the Community Code on medicinal products 
for human use, foresees a number of 
important changes, the most important of 
which are as follows: 
• The decentralised approval procedure, 
which operates alongside the mutual 
recognition procedure and whereby a 
reference member state issues its own 
assessment report on a proposed new 
product. This is circulated to other 
Member States, who can issue their own 
marketing authorisations on this basis, 
• A global Marketing Authorisation, 
which covers all future forms, strengths, 
routes of administration, extensions and 
variations to a product. This will limit 
the ability of generic pharmaceutical 
companies from making minor changes to 
Marketing Authorisation Applications,
• Definition of a generic product as 
that with the same quantitative and 
qualitative composition as a reference 
product and that has been shown to 
be bioequivalent to this product. This 
necessarily includes all salts, esters, 
isomers, complexes and derivatives of 
that substance, unless they differ in 
terms of efficacy and/or safety,
• Similar biological medicines, or 
“biosimilars”, regarded as “comparable” 
versions of biological drugs. This lays 
down a clear and firm legal pathway for 
their registration and is complemented 
by scientific guidelines from the EMEA,
• Sunset clause, whereby the marketing 
authorisation of product not placed on 
the market within three years of the date 
of its date of issue can be withdrawn.  
Companies will therefore be required to 
notify the regulatory authorities when 
they market a product,
• Market exclusivity is harmonised 
throughout the EU, whereby each newly 
approved drug benefits from eight 
years data exclusivity. This is extended 
by a further two years, during which 
generic versions may not be placed on 
the market, but can nevertheless be 
developed, submitted and authorised 
without infringing the originator’s patent 
rights. Marketing can only commence 
after expiry of this period, or one year 
later again, if within the first eight years, 
a product gains a new indication deemed 
to be of “…significant clinical benefit in 
comparison with other therapies”. 
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Small and medium-sized 
enterprises (SMEs)
One of the more innovative provisions 
of the new legislation package is the range 
of incentives offered to the small- and 
medium-sized enterprise sector operating 
in the field of pharmaceuticals. Under 
the terms of the legislation, considerable 
savings can be made in the seeking of 
various degrees of scientific advice and 
inspection fees at EMEA by reductions of 
up to 90% and the deferral of payments 
for such advice until after successful 
authorisation of products. 
According to the terms of Commission 
Recommendation 200/61/EC,10 a small- or 
medium-sized enterprise is defined as 
one with fewer than 250 employees, an 
annual turnover not exceeding €50m and a 
balance sheet not exceeding €m. A small 
enterprise has fewer than 50 employees, 
an annual turnover/annual balance sheet 
not exceeding €10m and a micro enterprise 
has less than 10 employees with an annual 
turnover/annual balance sheet of less than 
€2m. 
To determine which companies are 
eligible for SME incentives, the EMEA will 
apply the definition of micro, small and 
medium-sized enterprises provided in this 
recommendation. 
The main provisions of the legislation 
are as follows11: 
• Administrative and procedural assistance 
from the SME Office at EMEA, 
• Fee reductions for scientific advice, 
inspections and (for veterinary 
medicines) establishment of maximum 
residue limits, 
• Fee exemptions for certain administrative 
services of the EMEA, 
• Deferral of the fee payable for an 
application for marketing authorisation 
or related inspection, 
• Conditional fee exemption where 
scientific advice is followed and a 
marketing authorisation application is 
not successful, 
• Assistance with translations of the 
product information documents 
submitted in the application for 
marketing authorisation.
A responsible and especially dedicated 
office has been established at the EMEA for 
the submission of requests for designation 
of SME status and to answer further 
queries.12 A comprehensive guide has been 
published giving further information. 1 
Seventh framework programme 
It is intended that the Joint Technology 
Initiative for Innovative Medicines will 
be an integral and yet autonomous part 
of the Seventh Research Framework 
Programme.1  In this, collaborative 
research will constitute the bulk and the 
core of EU research funding. The objective 
is to establish, in the major fields of 
advancement of knowledge, excellent 
research projects and networks able to 
attract researchers and investments from 
Europe and the entire world.
Within the health domain, the primary 
concern remains to improve the health of 
European citizens while at the same time to 
increase the competitiveness of European 
health-related industries and businesses. 
Emphasis will be put on bringing the fruits 
of research to market as soon as possible 
in the form of safe and effective clinical 
applications, new therapies, methods 
for health promotion and prevention, 
diagnostic tools and technologies, as well 
as sustainable and efficient healthcare 
systems.
Activities extend to three  main areas : 
• Biotechnology, generic tools and 
technologies for human health, including 
research in molecular screening, 
diagnostics, alternatives to animal 
testing
• Translating research for human health, 
including ageing, brain diseases, 
infectious diseases and major diseases
• Optimising the delivery of healthcare 
to European citizens, comprising more 
efficient use of health care interventions 
All activities will be carried out in 
pursuit of the general objectives described 
in Article 16 of the Treaty in contributing 
towards the creation of a knowledge-based 
society, and to build on a European 
Research Area for all European citizens.
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